Kyverna Therapeutics: 'Strong Buy' On ElevateBio Deal And RA Program Advancement
· seekingalpha.com
Kyverna Therapeutics stays a Strong Buy as miv-cel advances in SPS, gMG & refractory RA; BLA by Q4 2026 and key trial catalysts ahead. Click to know more.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...